Tag: Hormones: Male
Testosterone Treatment Does Not Cut Fracture Incidence in Men With Hypogonadism
Findings show no reduction in clinical fracture among middle-aged, older men with hypogonadism
Hematocrit Within Normal Range With Testosterone Gender-Affirming Therapy
Mean hematocrit ranged from 41.84 to 45.68 percent for those receiving testosterone as gender-affirming hormone therapy
Testosterone Efficacious for Correcting Anemia in Middle-Aged Men
Fewer men without anemia developed anemia with testosterone replacement therapy versus placebo
Multiple Factors Associated With Sex Hormone Variation in Men
Testosterone levels appear to decline among men older than 70 years; inverse link seen for testosterone with BMI
Effect of Testosterone Examined From Adolescence Into Adulthood
Effect of testosterone on anterior prefrontal cortex engagement decreases from middle-to-late adolescence, then shifts into activational role
ENDO: Testosterone-Replacement Noninferior to Placebo for Cardiovascular Events
Findings seen in middle-aged men with preexisting or high risk of cardiovascular disease and hypogonadism
Direct-to-Consumer Testosterone Not Offered in Accordance With Guidelines
Most direct-to-consumer platforms offer testosterone therapy despite consumer reporting normal testosterone levels, free testosterone
Standard Testosterone Threshold Not Accurate for Younger Men
Age-specific testosterone cutoffs show each one-year increase in age tied to a 4.3-ng/dL decrease in testosterone level
COVID-19 Hospitalization Risk Higher for Men With Hypogonadism
Odds of hospitalization higher for men receiving inadequate TTh versus those with normal testosterone concentration while receiving TTh
Testosterone Therapy for Hypogonadism Not Tied to Increased CV Risk
No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety